1. Comparison of the Roche cobas 6800 SARS-CoV-2 test and the Taiwan CDC protocol for the molecular diagnosis of COVID-19
- Author
-
Huey Ling You, Meng-Chih Lin, and Chen Hsiang Lee
- Subjects
0301 basic medicine ,Medicine (General) ,Emergency Use Authorization ,medicine.medical_specialty ,QH301-705.5 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,RT-PCR ,Taiwan ,Brief Communication ,medicine.disease_cause ,03 medical and health sciences ,R5-920 ,0302 clinical medicine ,COVID-19 Testing ,Clinical Protocols ,Viral Envelope Proteins ,Pandemic ,Molecular diagnostics ,Medicine ,Humans ,Viral load ,Biology (General) ,Nucleocapsid ,Coronavirus ,Protocol (science) ,Coronavirus RNA-Dependent RNA Polymerase ,business.industry ,SARS-CoV-2 ,COVID-19 ,General Medicine ,Gold standard (test) ,RNA extraction ,Test (assessment) ,030104 developmental biology ,Molecular Diagnostic Techniques ,030220 oncology & carcinogenesis ,COVID-19 Nucleic Acid Testing ,Emergency medicine ,business - Abstract
The current coronavirus disease 2019 (COVID-19) pandemic has caused significant challenges throughout the world and a rapid, reliable diagnostic test is in high demand. Real-time reverse transcription polymerase chain reaction (RT-PCR) was one of the most quickly established methods of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection and is considered to be the gold standard. In this report, we share our experience of using two different testing platforms: the cobas 6800 SARS-CoV-2 test, an automated system that was recently granted Emergency Use Authorization by the FDA, and a laboratory-developed test based on the protocol from the Taiwan Centers for Disease Control (CDC). There was an overall 96.2% agreement between the two platforms. However, the positive agreement between the two platforms was only 80.0%. We found 3 instances of discordance between the two systems and this emphasized the need for timely diagnosis with a reliable testing platform.
- Published
- 2020